» Authors » Saskia Meyer

Saskia Meyer

Explore the profile of Saskia Meyer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 403
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Spasevska I, Sharma A, Steen C, Josefsson S, Blaker Y, Kolstad A, et al.
Blood Adv . 2023 Sep; 7(23):7216-7230. PMID: 37695745
Tumor-infiltrating regulatory T cells (Tregs) contribute to an immunosuppressive tumor microenvironment. Despite extensive studies, the prognostic impact of tumor-infiltrating Tregs in B-cell non-Hodgkin lymphomas (B-NHLs) remains unclear. Emerging studies suggest...
2.
Meyer S, Blaas I, Bollineni R, Delic-Sarac M, Tran T, Knetter C, et al.
Cell Rep . 2023 Jan; 42(1):111995. PMID: 36656713
The emergence of SARS-CoV-2 variants of concern (VOC) is driven by mutations that mediate escape from neutralizing antibodies. There is also evidence that mutations can cause loss of T cell...
3.
Riise J, Meyer S, Blaas I, Chopra A, Tran T, Delic-Sarac M, et al.
Br J Haematol . 2022 Mar; 197(6):697-708. PMID: 35254660
B-cell depletion induced by anti-cluster of differentiation 20 (CD20) monoclonal antibody (mAb) therapy of patients with lymphoma is expected to impair humoral responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)...
4.
Buspavanich P, Adli M, Himmerich H, Berger M, Busche M, Schlattmann P, et al.
J Psychiatr Res . 2021 Jul; 141:287-292. PMID: 34271459
Introduction: Cytokines might play a key role in the pathophysiology of major depressive disorder (MDD). The speed of onset of depressive episodes has been discussed as an important clinical parameter...
5.
Mester S, Evers M, Meyer S, Nilsen J, Greiff V, Sandlie I, et al.
MAbs . 2021 Mar; 13(1):1893888. PMID: 33691596
Albumin has a serum half-life of 3 weeks in humans. This feature can be used to improve the pharmacokinetics of shorter-lived biologics. For instance, an albumin-binding domain (ABD) can be...
6.
Evers M, Ten Broeke T, Jansen J, Nederend M, Hamdan F, Reiding K, et al.
MAbs . 2020 Aug; 12(1):1795505. PMID: 32744145
Current combination therapies elicit high response rates in B cell malignancies, often using CD20 antibodies as the backbone of therapy. However, many patients eventually relapse or develop progressive disease. Therefore,...
7.
Meyer S, Evers M, Jansen J, Buijs J, Broek B, Reitsma S, et al.
Br J Haematol . 2018 Feb; 180(6):808-820. PMID: 29468712
Based on their mechanisms-of-action, CD20 monoclonal antibodies (mAbs) are grouped into Type I [complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC)] and Type II [programmed cell death (PCD) and ADCC]...
8.
Lohse S, Loew S, Kretschmer A, Jansen J, Meyer S, Ten Broeke T, et al.
Br J Haematol . 2017 Apr; 181(3):413-417. PMID: 28449349
No abstract available.
9.
Graske J, Meyer S, Schmidt A, Schmidt S, Laporte Uribe F, Thyrian J, et al.
Pflege . 2016 Mar; 29(2):93-101. PMID: 26974281
Background: Regional dementia care networks become more and more important in the care for community-dwelling persons with dementia (PwD). However, the quality of life of PwD, served by dementia care...
10.
Wolf-Ostermann K, Meyer S, Schmidt A, Schritz A, Holle B, Wubbeler M, et al.
Z Gerontol Geriatr . 2016 Jan; 50(1):21-27. PMID: 26779703
Background: In Germany a growing number of community-based support services for people with dementia (PwD) and their caregivers are organized in dementia care networks (DCN), which provide a single point...